Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$6.44 -1.7%	$8.20	$3.16 ▼ $10.13	$1.50B	0.85	6.14 million shs	3.73 million shs
BFRA Biofrontera	$2.60	$2.95	$2.09 ▼ $7.54	$73.73M	1.02	27,512 shs	7,263 shs
FTSV Forty Seven	$95.51	$95.51	$5.53 ▼ $95.51	$4.60B	0.4	1.61 million shs	N/A
OPTN OptiNose	$0.93 -8.8%	$1.51	$0.90 ▼ $2.10	$104.51M	-0.24	534,927 shs	548,193 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-1.68%	-12.62%	-19.70%	-22.22%	+31.43%
BFRA Biofrontera	0.00%	0.00%	0.00%	0.00%	0.00%
FTSV Forty Seven	0.00%	0.00%	0.00%	0.00%	0.00%
OPTN OptiNose	-9.05%	-25.19%	-46.06%	-31.79%	-52.67%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	3.9283 of 5 stars	3.6	2.0	0.0	4.4	2.6	1.7	0.6
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	3.6778 of 5 stars	3.5	3.0	0.0	4.2	0.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.11	Buy	$12.69	97.01% Upside
BFRA Biofrontera	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A
OPTN OptiNose	3.00	Buy	$4.00	331.17% Upside

Current Analyst Ratings

Latest FTSV, BFRA, OPTN, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2024	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$13.00 ➝ $14.00
4/5/2024	ARDX Ardelyx	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/5/2024	ARDX Ardelyx	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00
2/23/2024	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$12.00 ➝ $15.00
2/23/2024	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$124.46M	12.04	N/A	N/A	$0.72 per share	8.94
BFRA Biofrontera	$36.19M	2.04	N/A	N/A	$0.35 per share	7.43
FTSV Forty Seven	$15.68M	293.33	N/A	N/A	$7.52 per share	12.70
OPTN OptiNose	$70.99M	1.47	N/A	N/A	($0.77) per share	-1.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$66.07M	-$0.30	N/A	64.40	N/A	-53.08%	-43.57%	-26.03%	5/1/2024 (Estimated)
BFRA Biofrontera	-$14.88M	-$0.73	N/A	∞	N/A	-59.44%	-93.31%	-24.02%	N/A
FTSV Forty Seven	-$87.62M	-$2.34	N/A	N/A	N/A	N/A	-50.38%	-44.35%	N/A
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)

Latest FTSV, BFRA, OPTN, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million
2/22/2024	12/31/2023	ARDX Ardelyx	-$0.09	-$0.12	-$0.03	-$0.12	$34.26 million	$34.36 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
BFRA Biofrontera	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	0.30	4.88	4.64
BFRA Biofrontera	0.13	1.26	1.13
FTSV Forty Seven	N/A	14.81	14.81
OPTN OptiNose	N/A	0.60	0.55

Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
BFRA Biofrontera	60.07%
FTSV Forty Seven	71.77%
OPTN OptiNose	85.60%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.50%
BFRA Biofrontera	N/A
FTSV Forty Seven	37.40%
OPTN OptiNose	2.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	267	232.69 million	219.89 million	Optionable
BFRA Biofrontera	138	28.36 million	N/A	Not Optionable
FTSV Forty Seven	57	48.16 million	N/A	Not Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable

FTSV, BFRA, OPTN, and ARDX Headlines

Source	Headline
	Optinose to Present at Needham Virtual Healthcare Conference msn.com - April 7 at 9:30 AM
	OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago finance.yahoo.com - April 6 at 2:26 PM
	Optinose to Present at the Needham Virtual Healthcare Conference globenewswire.com - April 4 at 4:01 PM
	Michael F. Marino III Sells 15,059 Shares of OptiNose, Inc. (NASDAQ:OPTN) Stock insidertrades.com - March 20 at 7:32 AM
	Insider Selling: OptiNose, Inc. (NASDAQ:OPTN) Insider Sells 15,059 Shares of Stock marketbeat.com - March 19 at 1:24 PM
	Optinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps finanznachrichten.de - March 16 at 1:18 PM
	OptiNose granted FDA nod to expand labeling for sinusitis therapy msn.com - March 16 at 1:18 PM
	Bucks County's Optinose wins FDA approval for wider use of flagship product bizjournals.com - March 15 at 8:58 PM
	XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps globenewswire.com - March 15 at 3:34 PM
	Optinose primed for FDA ruling on Xhance that could 'reshape' its future bizjournals.com - March 13 at 8:17 PM
	US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results finance.yahoo.com - March 10 at 1:35 PM
	OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript seekingalpha.com - March 10 at 12:26 AM
	OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 8 at 12:56 PM
	OptiNose Full Year 2023 Earnings: EPS Beats Expectations finance.yahoo.com - March 8 at 7:55 AM
	OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ... finance.yahoo.com - March 7 at 4:14 PM
	OPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023 investorplace.com - March 7 at 2:01 PM
	Optinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights finanznachrichten.de - March 7 at 10:19 AM
	Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights finance.yahoo.com - March 7 at 10:19 AM
	OptiNose reports mixed results; initiates Q1 and FY24 outlook msn.com - March 7 at 10:19 AM
	OptiNose: Q4 Earnings Snapshot washingtonpost.com - March 7 at 10:19 AM
	OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates zacks.com - March 7 at 9:16 AM
	Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights globenewswire.com - March 7 at 7:00 AM
	OptiNose's Earnings: A Preview benzinga.com - March 6 at 6:45 PM
	Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results globenewswire.com - February 29 at 4:40 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ardelyx

NASDAQ:ARDX

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Biofrontera

NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Forty Seven

NASDAQ:FTSV

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial